Advanced

Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI

Vos, Stephanie; van Rossum, Ineke; Burns, Leah; Knol, Dirk; Scheltens, Philip; Soininen, Hilkka; Wahlund, Lars-Olof; Hampel, Harald; Tsolaki, Magda and Minthon, Lennart LU , et al. (2012) In Neurobiology of Aging 33(10). p.2272-2281
Abstract
Our aim was to identify the best diagnostic test sequence for predicting Alzheimer's disease (AD)-type dementia in subjects with mild cognitive impairment (MCI) using cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) biomarkers. We selected 153 subjects with mild cognitive impairment from a multicenter memory clinic-based cohort. We tested the CSF beta amyloid (A beta)1-42/tau ratio using enzyme-linked immunosorbent assay (ELISA) and hippocampal volumes (HCVs) using the atlas-based learning embeddings for atlas propagation (LEAP) method. Outcome measure was progression to AD-type dementia in 2 years. At follow-up, 48 (31%) subjects converted to AD-type dementia. In multivariable analyses, CSF A beta 1-42/tau and HCV predicted... (More)
Our aim was to identify the best diagnostic test sequence for predicting Alzheimer's disease (AD)-type dementia in subjects with mild cognitive impairment (MCI) using cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) biomarkers. We selected 153 subjects with mild cognitive impairment from a multicenter memory clinic-based cohort. We tested the CSF beta amyloid (A beta)1-42/tau ratio using enzyme-linked immunosorbent assay (ELISA) and hippocampal volumes (HCVs) using the atlas-based learning embeddings for atlas propagation (LEAP) method. Outcome measure was progression to AD-type dementia in 2 years. At follow-up, 48 (31%) subjects converted to AD-type dementia. In multivariable analyses, CSF A beta 1-42/tau and HCV predicted AD-type dementia regardless of apolipoprotein E (APOE) genotype and cognitive scores. Test sequence analyses showed that CSF A beta 1-42/tau increased predictive accuracy in subjects with normal HCV (p < 0.001) and abnormal HCV (p = 0.025). HCV increased predictive accuracy only in subjects with normal CSF A beta 1-42/tau (p = 0.014). Slope analyses for annual cognitive decline yielded similar results. For selection of subjects for a prodromal AD trial, the best balance between sample size and number of subjects needed to screen was obtained with CSF markers. These results provide further support for the use of CSF and magnetic resonance imaging biomarkers to identify prodromal AD. (c) 2012 Elsevier Inc. All rights reserved. (Less)
Please use this url to cite or link to this publication:
@article{7993845a-d510-43b2-8e97-6275b80aec22,
  abstract     = {Our aim was to identify the best diagnostic test sequence for predicting Alzheimer's disease (AD)-type dementia in subjects with mild cognitive impairment (MCI) using cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) biomarkers. We selected 153 subjects with mild cognitive impairment from a multicenter memory clinic-based cohort. We tested the CSF beta amyloid (A beta)1-42/tau ratio using enzyme-linked immunosorbent assay (ELISA) and hippocampal volumes (HCVs) using the atlas-based learning embeddings for atlas propagation (LEAP) method. Outcome measure was progression to AD-type dementia in 2 years. At follow-up, 48 (31%) subjects converted to AD-type dementia. In multivariable analyses, CSF A beta 1-42/tau and HCV predicted AD-type dementia regardless of apolipoprotein E (APOE) genotype and cognitive scores. Test sequence analyses showed that CSF A beta 1-42/tau increased predictive accuracy in subjects with normal HCV (p &lt; 0.001) and abnormal HCV (p = 0.025). HCV increased predictive accuracy only in subjects with normal CSF A beta 1-42/tau (p = 0.014). Slope analyses for annual cognitive decline yielded similar results. For selection of subjects for a prodromal AD trial, the best balance between sample size and number of subjects needed to screen was obtained with CSF markers. These results provide further support for the use of CSF and magnetic resonance imaging biomarkers to identify prodromal AD. (c) 2012 Elsevier Inc. All rights reserved.},
  author       = {Vos, Stephanie and van Rossum, Ineke and Burns, Leah and Knol, Dirk and Scheltens, Philip and Soininen, Hilkka and Wahlund, Lars-Olof and Hampel, Harald and Tsolaki, Magda and Minthon, Lennart and Handels, Ron and L'Italien, Gilbert and van der Flier, Wiesje and Aalten, Pauline and Teunissen, Charlotte and Barkhof, Frederik and Blennow, Kaj and Wolz, Robin and Rueckert, Daniel and Verhey, Frans and Visser, Pieter Jelle},
  issn         = {1558-1497},
  keyword      = {Alzheimer's disease (AD),Dementia,Mild cognitive impairment (MCI),cerebrospinal fluid (CSF),A beta 1-42,Tau,Magnetic resonance imaging,(MRI),Volumetry,Hippocampus,Diagnostic test sequence},
  language     = {eng},
  number       = {10},
  pages        = {2272--2281},
  publisher    = {Elsevier},
  series       = {Neurobiology of Aging},
  title        = {Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI},
  url          = {http://dx.doi.org/10.1016/j.neurobiolaging.2011.12.017},
  volume       = {33},
  year         = {2012},
}